ObsEva SA OBSEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.00–0.40
- Bid/Ask
- — / —
- Market Cap
- $585,886.44
- Volume/Avg
- 50,231 / 22,671
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women’s reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.obseva.com
Valuation
|
Metric
|
OBSEF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OBSEF
|
|---|---|
Quick Ratio | 1.21 |
Current Ratio | 2.23 |
Interest Coverage | −2.24 |
Quick Ratio
OBSEF
Profitability
|
Metric
|
OBSEF
|
|---|---|
Return on Assets (Normalized) | −41.53% |
Return on Equity (Normalized) | −227.14% |
Return on Invested Capital (Normalized) | −41.89% |
Return on Assets
OBSEF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jqxqcdvwlt | Wkbdz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dncprytr | Brtcg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kqkgrgw | Xftfnhh | $97.8 Bil | |
MRNA
| Moderna Inc | Hlhnlry | Dsmd | $41.3 Bil | |
ARGX
| argenx SE ADR | Lqbdlyr | Nmkm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Vdqvrtvf | Tnkq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pcywfstts | Bwclypm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nkjxbrns | Fdmxwzq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dnsdpqdj | Mtnfgd | $12.5 Bil | |
INCY
| Incyte Corp | Ygnvhyhrq | Zngfsns | $11.6 Bil |